About Us

Pioneers

We use our knowledge in HPV diagnostics realising an optimal cancer patient management

Abviris addresses the globally increasing problem of cancer caused by the human papillomavirus (HPV). We are dedicated to improving the clinical outcomes of patients and enable clinicians worldwide to fight HPV-induced tumours, including head and neck cancer, penile and anal tumours, vaginal and vulvar cancer and of course cervical cancer. Our patented diagnostics support factors that are key to a favourable prognosis, such as early tumour detection and post-therapy patient management. As pioneers in HPV serology, we develop highly innovative solutions, including Prevo-Check®, the world´s first entire-body screening test for HPV16-induced cancer, which can be performed with a single drop of blood within minutes.

About

2020
Jun 11

Q2 2020

Findings from a multicentre European clinical study evaluating the DRH1 tumour marker test have been published in Ebiomedicine, one of the Lancet’s stable of medical journals. Find out more about the study here.

2019
Nov 28

Q4 2019

Study with Prevo-Check® wins "Pilot of the Year" UK Diagnostics Award

Oct 01

Q4 2019

GALS project kick-off for development of US market access strategy

Jul 15

Q3 2019

Kick-off for cooperation between Abviris and DermaMed

Jun 30

Q2 2019

Establishment of Advisory Board

Feb 28

Q1 2019

Pre-Series A Financing

2018
Sep 28

Q3 2018

Launch of business development

Jul 28

Q1 2018

> 5000 study patients enrolled

2017
Sep 28

Q4 2017

400 customers, CE mark PT-monitor®

2016
Sep 28

Q4 2016

Filing patent 3

2015
Sep 28

Q3 2015

> 1500 patients tested in 4 clinical trials

Jul 28

Q2 2015

Test market for Prevo-Check® in Germany

May 28

Q1 2015

International 1st clinical trial

2014
Sep 28

Q3 2014

CE mark

PrevoCheck®

Jul 28

Q2 2014

Abviris foundation

2011
Sep 28

2011 and 2012

Filing patent 1 and 2

2010
Sep 28

2010-2014

Scientific and clinical research period resulting in key findings